ISLAMABAD, PAKISTAN — In a major breakthrough for Pakistan’s healthcare sector and industrial localization goals, the two-day Pakistan–China Pharmaceutical & Healthcare B2B Investment Conference successfully concluded in Islamabad.

The high-profile summit brought together over 500 delegates, including 150 elite Chinese pharmaceutical and biotechnology firms alongside 340 Pakistani enterprises. Graced by the Prime Minister of Pakistan and senior national leadership—including the Director General of the Special Investment Facilitation Council (SIFC) and Federal Minister for National Health Services Syed Mustafa Kamal—the event marks a massive stride forward under the industrial phase of the China-Pakistan Economic Corridor (CPEC 2.0).

A Strategic Shift to Local Production and Tech Transfer

The conference focused heavily on addressing a critical vulnerability in Pakistan’s medical supply chain: while the country indigenously manufactures roughly 85% of its finished medicines, it currently imports nearly 90% of its active raw materials.

Organized through the joint synergy of the SIFC, the Ministry of National Health Services, Regulations & Coordination, the Drug Regulatory Authority of Pakistan (DRAP), and the Trade Development Authority of Pakistan (TDAP), the summit established structured avenues for Chinese investors to partner with local industries.

Key focus sectors included:

• Active Pharmaceutical Ingredients (APIs): Localizing raw material manufacturing to reduce import reliance.
• Biotechnology & Vaccines: Creating cutting-edge infrastructure for biologics, insulin, and human vaccines.
• Medical Devices & Diagnostics: Scaling local production of high-tech clinical equipment.

“The pharmaceutical industry is directly linked to public health and remains a top priority. Investment in this sector will provide access not only to Pakistan’s vast domestic market but also open doors to regional and global exports.”

— Federal Health Minister Syed Mustafa Kamal

Red Tape to Red Carpet: Slashing Regulatory Timelines

Addressing Chinese business leaders, officials highlighted major regulatory overhauls driven by DRAP and the SIFC to maximize the ease of doing business.

Through aggressive institutional digitization, the timeline for registering advanced medical devices in Pakistan has been radically reduced from two and a half years down to just 20 days. Furthermore, the health minister expressed confidence that DRAP will achieve the World Health Organization’s (WHO) prestigious Maturity Level 3 (ML3) accreditation by April next year, a milestone that will unlock pharmaceutical export access to more than 100 international markets.

Breakthrough Commercial Success

The conference yielded phenomenal economic results, culminating in the signing of nine major agreements and MoUs valued at over $440 million.

These cross-border business agreements pave the way for immediate foreign direct investment (FDI), large-scale technology transfers, and joint ventures—firmly anchoring Pakistan’s position as an emerging, highly competitive hub for healthcare innovation and trade in the region.